Skip to main content
NCBI home page
Gut logoLink to Gut
. 1991 Apr;32(4):435–438. doi: 10.1136/gut.32.4.435

Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.

K D Bardhan 1, J Naesdal 1, G Bianchi Porro 1, M Petrillo 1, M Lazzaroni 1, R F Hinchliffe 1, M Thompson 1, P Morris 1, M J Daly 1, N J Carroll 1, et al.
PMCID: PMC1379086  PMID: 1673953

Abstract

We tested the hypothesis that the gastric H+/K+ adenosine triphosphatase inhibitor, omeprazole, because of its different mode of action and pronounced inhibitory effect on gastric acid secretion, may be more effective in peptic ulcer that is refractory to histamine H2 receptor antagonist treatment than continuing the same therapy. Altogether 107 patients (duodenal ulcer, n = 88; prepyloric ulcer, n = 14; gastric ulcer, n = 3; mixed sites, n = 2) with refractory peptic ulcer - that is ulcer unhealed after at least two months' treatment with cimetidine 0.8 g or 1 g daily or with ranitidine 0.3 g daily - were randomly allocated to receive either omeprazole 40 mg daily (n = 54) or to continue treatment with the same H2 receptor antagonist and at the same dose (n = 53) for up to eight weeks. The patients in the two treatment groups were well matched demographically. Healing by 'intent to treat' analysis was as follows: at four weeks, omeprazole 46 of 54 (85%), H2 receptor antagonist 18 of 53 (34%) (p less than 0.0001); and at eight weeks, 52 of 54 (96%) and 30 of 53 (57%) respectively (p less than 0.0001). One patient was lost to follow up but of the 22 patients whose ulcers were shown to be unhealed at endoscopy after receiving continued H2 receptor antagonist treatment, 21 healed in four to eight weeks when changed to omeprazole. Daytime epigastric pain cleared at four weeks in 43 of 47 (91%) patients on omeprazole and in 32 of 46 (70%) on H2 receptor antagonists (p=0.01) and relief of all dyspeptic symptoms occurred in 39 of 47 (83%) and 23 of 45 (51%) (p=0.0009) patients respectively. Adverse events occurred in 11 of 54 (20%) patients on omeprazole and in 12 of 35 (34%) on cimetidine but in none on ranitidine. The events were mild and none required treatment withdrawal. The commonest event in patients on omeprazole was loose stools or diarrhoea (n=5). Omeprazole was significantly better than continued H2 receptor antagonist treatment for the short term management of refractory peptic ulcer as judged by healing rate and pain relief, and it was safe.

Full text

PDF
435

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amouretti M., Ansenay M., Bader J. P., Baillet J., Bel A., Belaïche J., Benzenou A., Bertrand G., Bonfils S., Boucekkine T. Efficacité de la ranitidine et de la cimétidine dans le traitement de l'ulcère duodénal ou gastrique résistant à un traitement initial par la cimétidine. Essai thérapeutique contrôlé multicentrique. Gastroenterol Clin Biol. 1985 Feb;9(2):147–152. [PubMed] [Google Scholar]
  2. Bardhan K. D. Refractory duodenal ulcer. Gut. 1984 Jul;25(7):711–717. doi: 10.1136/gut.25.7.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bardhan K. D., Thompson M., Bose K., Hinchliffe R. F., Crowe J., Weir D. G., McCarthy C., Walters J., Thomson T. J., Thompson M. H. Combined anti-muscarinic and H2 receptor blockade in the healing of refractory duodenal ulcer. A double blind study. Gut. 1987 Nov;28(11):1505–1509. doi: 10.1136/gut.28.11.1505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bianchi Porro G., Parente F., Lazzaroni M. Tripotassium dicitrato bismuthate (TDB) versus two different dosages of cimetidine in the treatment of resistant duodenal ulcers. Gut. 1987 Jul;28(7):907–911. doi: 10.1136/gut.28.7.907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brunner G., Creutzfeldt W., Harke U., Lamberts R. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment. Digestion. 1988;39(2):80–90. doi: 10.1159/000199610. [DOI] [PubMed] [Google Scholar]
  6. Collen M. J., Stanczak V. J., Ciarleglio C. A. Refractory duodenal ulcers (nonhealing duodenal ulcers with standard doses of antisecretory medication). Dig Dis Sci. 1989 Feb;34(2):233–237. doi: 10.1007/BF01536057. [DOI] [PubMed] [Google Scholar]
  7. Dal Monte P. R., D'Imperio M., Ferri M., Fratucello F., del Soldato P. A combination of pirenzepine and cimetidine: a new approach to treatment of duodenal ulcer in "non-responders". Hepatogastroenterology. 1985 Jun;32(3):126–128. [PubMed] [Google Scholar]
  8. Delchier J. C., Isal J. P., Eriksson S., Soule J. C. Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers. Gut. 1989 Sep;30(9):1173–1178. doi: 10.1136/gut.30.9.1173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Guslandi M. More about refractory duodenal ulcers. Gut. 1984 Dec;25(12):1433–1434. doi: 10.1136/gut.25.12.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lam S. K., Lee N. W., Koo J., Hui W. M., Fok K. H., Ng M. Randomised crossover trial of tripotassium dicitrato bismuthate versus high dose cimetidine for duodenal ulcers resistant to standard dose of cimetidine. Gut. 1984 Jul;25(7):703–706. doi: 10.1136/gut.25.7.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Lanzon-Miller S., Pounder R. E., Hamilton M. R., Ball S., Chronos N. A., Raymond F., Olausson M., Cederberg C. Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther. 1987 Jun;1(3):239–251. doi: 10.1111/j.1365-2036.1987.tb00623.x. [DOI] [PubMed] [Google Scholar]
  12. Naesdal J., Bodemar G., Walan A. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol. 1984 Oct;19(7):916–922. [PubMed] [Google Scholar]
  13. Sharma B. K., Walt R. P., Pounder R. E., Gomes M. D., Wood E. C., Logan L. H. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut. 1984 Sep;25(9):957–964. doi: 10.1136/gut.25.9.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tulassay Z., Papp J., Szathmári M. Combination of pirenzepine and cimetidine in the therapy of duodenal ulcer. Am J Gastroenterol. 1987 Nov;82(11):1217–1217. [PubMed] [Google Scholar]
  15. Tytgat G. N., Lamers C. B., Hameeteman W., Jansen J. M., Wilson J. A. Omeprazole in peptic ulcers resistant to histamine H2-receptor antagonists. Aliment Pharmacol Ther. 1987 Feb;1(1):31–38. doi: 10.1111/j.1365-2036.1987.tb00603.x. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES